Advertisement

American Journal of Clinical Dermatology

, Volume 18, Issue 6, pp 745–754 | Cite as

MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors

  • Antonio M. Grimaldi
  • Ester Simeone
  • Lucia Festino
  • Vito Vanella
  • Martina Strudel
  • Paolo A. Ascierto
Review Article

Abstract

The mitogen-activated protein kinase (MAPK) cascade is an intracellular signaling pathway involved in the regulation of cellular proliferation and the survival of tumor cells. Several different mutations, involving BRAF or NRAS, exert an oncogenic effect by activating the MAPK pathway, resulting in an increase in cellular proliferation. These mutations have become targets for new therapeutic strategies in melanoma and other cancers. Selective MEK inhibitors have the ability to inhibit growth and induce cell death in BRAF- and NRAS-mutant melanoma cell lines. MEK inhibitor therapy in combination with a BRAF inhibitor is more effective and less toxic than treatment with a BRAF inhibitor alone, and has become the standard of care for patients with BRAF-mutated melanoma. Trametinib was the first MEK inhibitor approved for the treatment of BRAF-mutated metastatic melanoma not previously treated with BRAF inhibitors, and is also approved in combination with the BRAF inhibitor dabrafenib. Furthermore, cobimetinib is another MEK inhibitor approved for the treatment of BRAF-mutated metastatic melanoma in combination with a BRAF inhibitor, vemurafenib. The MEK inhibitor binimetinib in combination with the BRAF inhibitor encorafenib is in clinical development. The addition of an anti-PD-1/PD-L1 agent, such as pembrolizumab, durvalumab or atezolizumab, to combined BRAF and MEK inhibition has shown considerable promise, with several trials ongoing in metastatic melanoma. Binimetinib has also shown efficacy in NRAS-mutated melanoma patients. Future possibilities for MEK inhibitors in advanced melanoma, as well as other solid tumors, include their use in combination with other targeted therapies (e.g. anti-CDK4/6 inhibitors) and/or various immune-modulating antibodies.

Notes

Acknowledgements

The authors extend special thanks to Alessandra Trocino for providing excellent service and assistance.

Author contributions

Antonio M. Grimaldi and Paolo A. Ascierto prepared the manuscript collaboratively, with input from and approval of all co-authors. All authors read and approved the final manuscript.

Compliance with Ethical Standards

Funding

No funding was received for the preparation of this review.

Conflict of interest

Antonio M. Grimaldi has received honoraria from BMS, MSD, Novartis, and Roche Genentech, and had consultant/advisory roles for MSD and Novartis. Ester Simeone has received honoraria from BMS, Novartis, and Roche Genentech, and had a consultant/advisory role for BMS. Paolo A. Ascierto received research founding from BMS, Roche Genentech, and Array Biopharma, and had consulting/advisory roles for BMS, Roche Genentech, MSD, Novartis, Array Biopharma, Amgen, Merck Serono, and Pierre Fabre. Lucia Festino, Vito Vanella, and Martina Strudel declare no conflicts of interest.

References

  1. 1.
    Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37–40.CrossRefPubMedGoogle Scholar
  2. 2.
    Liebmann C. Regulation of MAP kinase activity by peptide receptor signaling pathway: paradigms of multiplicity. Cell Signal. 2001;13:777–85.CrossRefPubMedGoogle Scholar
  3. 3.
    Katz M, Amit I, Yaden Y, et al. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 2007;1773:1161–76.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell Signal. 2004;16:769–79.CrossRefPubMedGoogle Scholar
  5. 5.
    Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.CrossRefPubMedGoogle Scholar
  6. 6.
    Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.CrossRefPubMedGoogle Scholar
  7. 7.
    Goel VK, Lazar AJ, Warneke CL, et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006;126:154–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Röring M, Brummer T. Aberrant B-Raf signaling in human cancer—10 years from bench to bedside. Crit Rev Oncog. 2012;17:97–121.CrossRefPubMedGoogle Scholar
  9. 9.
    Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic BRaf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 2008;105:3041–6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439:358–62.CrossRefPubMedGoogle Scholar
  11. 11.
    Bedogni B, Welford SM, Kwan AC, et al. Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPR as mouse model. Mol Cancer Ther. 2006;5:3071–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol. 2005;5:350–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Hsueh C-T, Liu D, Wang H. Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomark Res. 2013;1:1.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273:18623–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–14.CrossRefPubMedGoogle Scholar
  16. 16.
    Long GV, Stroyakonskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–51.CrossRefPubMedGoogle Scholar
  17. 17.
    Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16:1389–98.CrossRefPubMedGoogle Scholar
  18. 18.
    Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76.CrossRefPubMedGoogle Scholar
  19. 19.
    Yamaguchi T, Kakefuda R, Tajima N, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011;39:23–31.PubMedGoogle Scholar
  20. 20.
    Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011;17:989–1000.CrossRefPubMedGoogle Scholar
  21. 21.
    Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:773–81.CrossRefPubMedGoogle Scholar
  22. 22.
    Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31:482–9.CrossRefPubMedGoogle Scholar
  23. 23.
    King AJ, Arnone MR, Bleam MR, et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One. 2013;8:e67583.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Long GV, Stroyakoversuskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88.CrossRefPubMedGoogle Scholar
  26. 26.
    Flaherty K, Davies MA, Grob JJ, et al. Genomic analysis and 3-y efficacy and safety update of COMBI-d: a phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. J Clin Oncol. 2016;34(Suppl). Abstract No. 9502.Google Scholar
  27. 27.
    Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma. Ann Oncol. 2016;27(Suppl 6):LBA40.Google Scholar
  29. 29.
    Planchard D, Besse B, Groen HJM, et al. An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928). J Clin Oncol. 2016;34(Suppl). Abstract No. 107.Google Scholar
  30. 30.
    Planchard D, Besse B, Groen HJ. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984–93.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Johnston S. XL518, a potent selective orally bioavailable MEK1 inhibitor, down-regulates the RAS/RAF/MEK/ERK pathway in vivo, resulting in tumor growth inhibition and regression in preclinical models. In: 19th AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics. San Francisco, CA; 2007. p.Abstract C209.Google Scholar
  32. 32.
    LoRusso P, Shapiro G, Pandya SS, et al. A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. J Clin Oncol. 2012;30(15 Suppl). Abstract No. 2566.Google Scholar
  33. 33.
    Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15:954–65.CrossRefPubMedGoogle Scholar
  34. 34.
    McArthur G, Dreno B, Atkinson V et al. Efficacy of long-term cobimetinib + vemurafenib in advanced BRAFV600-mutated melanoma: 3-year follow-up of coBRIM (Phase 3) and 4-year follow-up of BRIM7 (Phase 1b). Poster at Society for Melanoma Research 2016 Congress, 6–9 Nov 2016, Boston, MA.Google Scholar
  35. 35.
    Winski S, Anderson D, Bouhana K, et al. MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations. In: Proceedings of the 22nd EORTC–NCI–AACR symposium on molecular targets and cancer therapeutics. Berlin, Germany; 2010. Nov 16–19.Google Scholar
  36. 36.
    Bendell JC, Papadopoulos K, Jones SF, et al. A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors. Mol Cancer Ther. 2011;10(Suppl 1). Abstract No. B243.Google Scholar
  37. 37.
    Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non randomised, open-label phase 2 study. Lancet Oncol. 2013;14:249–56.CrossRefPubMedGoogle Scholar
  38. 38.
    VanHerpen C, et al. Overall survival and biomarker results from a phase 2 study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS-mutant melanoma. Ann Oncol. 2014;25:1–41.CrossRefGoogle Scholar
  39. 39.
    Dummer R, Schadendorf D, Ascierto PA, et al. Results of NEMO: a phase III trial of binimetinib (BINI) vsdacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. J Clin Oncol. 2016;34(Suppl). Abstract No. 9500.Google Scholar
  40. 40.
    Dummer R, Ascierto PA, Gogas H et al. Results of COLUMBUS Part 1: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in BRAF-mutant melanoma. Presented at the Society for Melanoma Research annual meeting, 6–9 Nov 2016, Boston, MA.Google Scholar
  41. 41.
    Van Herpen C, Postow MA, Carlino MS, et al. A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma. Presented at the 2015 European Cancer Congress, 25–29 Sep 2015, Vienna. Abstract No. 3300.Google Scholar
  42. 42.
    Minor DR, Puzanov I, Callahan MK, Hug BA, Hoos A. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. 2015;28:611–2.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ribas A, Butler M, Lutzky J, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol. 2015;33(Suppl). Abstract No. 3003.Google Scholar
  44. 44.
    RibasA, Hodi S, Lawrence DP, et al. Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: phase 1 KEYNOTE-022 study. J Clin Oncol. 2016;34(Suppl). Abstract No. 3014.Google Scholar
  45. 45.
    Hwu P, Hamid O, Gonzalez R. Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma. Ann Oncol. 2016;27(Suppl 6):vi379–400.Google Scholar
  46. 46.
    Infante J, Kim TM, Friedmann J, et al. Safety and clinical activity of atezolizumab combined with cobimetinib in metastatic melanoma. Presented at the Society for Melanoma Research annual meeting, 6–9 Nov 2016, Boston, MA.Google Scholar
  47. 47.
    Bendell JC, Kim TW, Goh BC, et al. Clinical activity of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol. 2016;34(Suppl). Abstract No. 3502.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Antonio M. Grimaldi
    • 1
  • Ester Simeone
    • 1
  • Lucia Festino
    • 1
  • Vito Vanella
    • 1
  • Martina Strudel
    • 1
  • Paolo A. Ascierto
    • 1
  1. 1.Unit of Melanoma, Cancer Immunotherapy and Innovative TherapyIstituto Nazionale Tumori Fondazione “G. Pascale”NaplesItaly

Personalised recommendations